Also, our ROC analysis indicates that KLK2 and KLK4 can be used as novel biomarkers for thyroid cancer, since previous studies have not reported any kallikreins as biomarkers for thyroid cancer. This evidence concerns the gene KLK2 and thyroid gland carcinoma.